The FDA has approved Rezvoglar, the second interchangeable biosimilar for Lantus (insulin glargine); the first was Semglee.
What is a biosimilar? It’s kind of like a generic drug, but in the case of biologics, it has to be highly similar and have no clinically-meaningful differences.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761215s000Orig2s000.lbl.pdf
